Fountain Healthcare Partners

Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates.

Genable Technologies Limited, a bio-pharmaceutical gene therapy company, develops gene therapies for the treatment of autosomal dominant genetic diseases. Its RhoNova product is designed for the treatment of patients with rhodopsin (RHO)-linked autosomal dominant retinitis pigmentosa– a debilitating, progressive form of inherited blindness resulting from various mutations in the RHO gene. Genable Technologies Limited was formerly known as Optigen Technologies Ltd. The company was incorporated in 1998 and is based in Dublin, Ireland. As of March 7, 2016, Genable Technologies Limited operates as a subsidiary of Spark Therapeutics, Inc.

KANDY THERAPEUTICS LIMITED develops non-hormonal treatment for multiple symptoms of the menopause including hot flashes and night time awakening. The company offers NT-814, a drug for common, chronic debilitating female sex-hormone related treatment. It provides non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms, enabling patients to receive treatment, and reduce symptoms of hormone related conditions. The company was founded in 2017 and is based in Stevenage, United Kingdom. KANDY THERAPEUTICS LIMITED operates as a subsidiary of Bayer Aktiengesellschaft.

Vivasure Medical Limited, a medical device company, engages in the research, development, and manufacture of arterial and venous closure devices based on its patented PerQseal technology. The company develops polymer implants and delivery systems that primarily focused on minimally invasive vessel closures in cardiology, interventional radiology, and vascular surgery areas. Its lead product is an absorbable patch-based large-bore percutaneous closure device that is designed to enable closure of large arteriotomies in transcatheter procedures, such as those used for transcatheter aortic valve replacement (TAVR) and endovascular aneurysm repair (EVAR). Vivasure Medical Limited was incorporated in 2008 and is based in Galway, Ireland.

Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.

Neurent Medical Limited develops medical device for treating rhinitis. The company offers a single-use device for ENT surgeons to treat both allergic and non-allergic rhinitis. The company was founded in 2015 and is headquartered in Galway, Ireland.

Civitas Therapeutics is a biopharmaceutical company that focuses on developing pulmonary delivery therapies. The Company develops therapeutics for the treatment of central nervous system and respiratory disorders. It serves patients throughout the United States.

Velicept Therapeutics, Inc., a clinical development company, develops and commercializes drugs that have the potential to improve patients’ lives by transforming the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Its lead program include Solabegron, a differentiated and selective compound that relaxes the bladder smooth muscle by stimulating beta 3-adrenoceptors, which is being investigated for OAB and IBS conditions that affect the quality of life. The company was founded in 2015 and is based in Malvern, Pennsylvania.

Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases, based on a breakthrough discovery showing that CXCR4 is a master regulator of inflammation. Ermium Therapeutics was founded in June 2019 by Jean-Philippe HERBEUVAL, Kurma Partners, Idinvest Partners, Domain Therapeutics and Erganeo. The company is based in Paris and has signed a worldwide exclusive license agreement on intellectual property from CNRS and University Paris Descartes (France) through an agreement with Erganeo, which supported the maturation of the project in an academic setting. In addition, Ermium Therapeutics recently won the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education.

MMI S.r.l manufactures and develops micro instruments to support surgical interventions at a dimensional scale. The company develops wristed micro instruments and their fabrication process. The company also develops and offers robotic platform. The company's proprietary robotic platform and wristed micro instruments simplifies reconstruction procedures after traumatic injuries and after tumor removal in breast, head, and bones. The company was founded in 2015 and is headquartered in Calci, Italy.

Velicept Therapeutics, Inc., a clinical development company, develops and commercializes drugs that have the potential to improve patients’ lives by transforming the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Its lead program include Solabegron, a differentiated and selective compound that relaxes the bladder smooth muscle by stimulating beta 3-adrenoceptors, which is being investigated for OAB and IBS conditions that affect the quality of life. The company was founded in 2015 and is based in Malvern, Pennsylvania.

Drug development firm focused on immunology. They are headquartered in Dublin, Ireland. Opsona Therapeutics is one of Europe's most innovative and dynamic drug development companies. We are at the forefront of drug development in immunology research, with particular focus on the innate immunity pathways. Since its founding in 2004, Opsona has validated and developed a series of exciting new drug candidates and strategies which modulate the human innate immune system. We are located in Dublin, Ireland.

Inotrem S.A discovers and develops novel treatments in the field of inflammatory pathologies with a focus on critical care. Its technology includes a TREM-1 inhibitor, nangibotide (LR12), that aims to control excessive inflammation in severe sepsis patients. The company was founded in 2013 and is based in Paris, France.

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.

XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease. The company's service focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patients with refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost effectively.

MMI S.r.l manufactures and develops micro instruments to support surgical interventions at a dimensional scale. The company develops wristed micro instruments and their fabrication process. The company also develops and offers robotic platform. The company's proprietary robotic platform and wristed micro instruments simplifies reconstruction procedures after traumatic injuries and after tumor removal in breast, head, and bones. The company was founded in 2015 and is headquartered in Calci, Italy.

Priothera Ltd develops orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies. It helps reduce egress of T cell subsets from lymphatic tissue. The company develops mocravimod to improve the curative potential of allogeneic haematopoietic stem cell transplant. Priothera Ltd was incorporated in 2020 and is based in Dublin, Ireland with additional location in Saint Louis, France.

KANDY THERAPEUTICS LIMITED develops non-hormonal treatment for multiple symptoms of the menopause including hot flashes and night time awakening. The company offers NT-814, a drug for common, chronic debilitating female sex-hormone related treatment. It provides non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms, enabling patients to receive treatment, and reduce symptoms of hormone related conditions. The company was founded in 2017 and is based in Stevenage, United Kingdom. KANDY THERAPEUTICS LIMITED operates as a subsidiary of Bayer Aktiengesellschaft.

Drug development firm focused on immunology. They are headquartered in Dublin, Ireland. Opsona Therapeutics is one of Europe's most innovative and dynamic drug development companies. We are at the forefront of drug development in immunology research, with particular focus on the innate immunity pathways. Since its founding in 2004, Opsona has validated and developed a series of exciting new drug candidates and strategies which modulate the human innate immune system. We are located in Dublin, Ireland.

Neuromod Devices Limited, a medical device company, specializes in the research and development of neuromodulation treatments for chronic tinnitus. Its mutebutton is a bi-modal neuromodulation device that focuses on promoting positive therapeutic change in the human nervous system. The company was founded in 2010 and is based in Dublin, Ireland.

Inotrem S.A discovers and develops novel treatments in the field of inflammatory pathologies with a focus on critical care. Its technology includes a TREM-1 inhibitor, nangibotide (LR12), that aims to control excessive inflammation in severe sepsis patients. The company was founded in 2013 and is based in Paris, France.

Chrono Therapeutics Inc., a digital transdermal drug delivery company, develops SmartStop, a digital nicotine replacement therapy. Its wearable solution tailors the timing and dose sizes of drugs, preempts predictable peak disease, and addiction symptoms with a device. The company was incorporated in 2003 and is based in Hayward, California.

Mainstay Medical Holdings plc, together with its subsidiaries, operates as a medical device company in Ireland, the United States, and Australia. It focuses on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat people with chronic low back pain by helping to restore control to the muscles that dynamically stabilise the lumbar spine. Mainstay Medical Holdings plc was founded in 2008 and is headquartered in Dublin, Ireland.

Palyon Medical Corporation is a medical device company developing technologies for the treatment of chronic pain, spasticity and other neurological diseases.

Neuravi Limited designs and develops clot retrieval devices for restoring blood flow in patients who have suffered ischemic strokes due to blockage of an artery to the brain. It offers EmboTrap revascularization devices for the treatment of acute ischemic strokes to patients in Belgium, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Norway, Spain, Sweden, and Switzerland. The company was incorporated in 2009 and is based in Galway, Ireland. As of April 10, 2017, Neuravi Limited operates as a subsidiary of DePuy Ireland Unlimited Company.

MMI S.r.l manufactures and develops micro instruments to support surgical interventions at a dimensional scale. The company develops wristed micro instruments and their fabrication process. The company also develops and offers robotic platform. The company's proprietary robotic platform and wristed micro instruments simplifies reconstruction procedures after traumatic injuries and after tumor removal in breast, head, and bones. The company was founded in 2015 and is headquartered in Calci, Italy.

Mainstay Medical Holdings plc, together with its subsidiaries, operates as a medical device company in Ireland, the United States, and Australia. It focuses on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat people with chronic low back pain by helping to restore control to the muscles that dynamically stabilise the lumbar spine. Mainstay Medical Holdings plc was founded in 2008 and is headquartered in Dublin, Ireland.

Neurent Medical Limited develops medical device for treating rhinitis. The company offers a single-use device for ENT surgeons to treat both allergic and non-allergic rhinitis. The company was founded in 2015 and is headquartered in Galway, Ireland.

Mainstay Medical Holdings plc, together with its subsidiaries, operates as a medical device company in Ireland, the United States, and Australia. It focuses on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat people with chronic low back pain by helping to restore control to the muscles that dynamically stabilise the lumbar spine. Mainstay Medical Holdings plc was founded in 2008 and is headquartered in Dublin, Ireland.

Inflazome is a biotech company that develops orally available drugs to address inflammatory diseases by targeting inflammasomes. The company's drugs block inflammasome signals, eliminating a root cause of inflammation, enabling healthcare institutions to avail targeted therapies for inflammatory diseases such as Parkinson's, Alzheimer's, atherosclerosis, and type 2 diabetes. The company was incorporated in 2016 and is headquartered in Dublin, Ireland.

Amarin Corporation is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease. Amarin’s lead candidate, AMR101, is currently being studied in two concurrently run pivotal Phase 3 trials. These trials are investigating the efficacy of AMR101 in lowering triglycerides in patients with very high triglycerides (>500mg/dl) and in patients with mixed dyslipidemia who are taking statins. Amarin’s cardiovascular programs capitalize on Amarin's expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease. Amarin is headquartered in Dublin, Ireland, and has its research and development headquartered in Mystic Connecticut, USA. Amarin is listed in the U.S. on NASDAQ (ticker: AMRN)

Neuromod Devices Limited, a medical device company, specializes in the research and development of neuromodulation treatments for chronic tinnitus. Its mutebutton is a bi-modal neuromodulation device that focuses on promoting positive therapeutic change in the human nervous system. The company was founded in 2010 and is based in Dublin, Ireland.

NeRRe Therapeutics Ltd. develops preclinical and clinical neurokinin (NK) receptor antagonists. The company focuses on NK-1 antagonist asset orvepitant as an oral treatment for intense pruritus induced by targeted anti-cancer therapies. It offers NT-814, a NK-1, 3 antagonist; NT-949, a Phase I ready NK-1 antagonist; and NT-432, a NK-1 antagonist clinical candidate. The company was founded in 2012 and is based in Stevenage, United Kingdom.

Mainstay Medical Holdings plc, together with its subsidiaries, operates as a medical device company in Ireland, the United States, and Australia. It focuses on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat people with chronic low back pain by helping to restore control to the muscles that dynamically stabilise the lumbar spine. Mainstay Medical Holdings plc was founded in 2008 and is headquartered in Dublin, Ireland.

Chrono Therapeutics Inc., a digital transdermal drug delivery company, develops SmartStop, a digital nicotine replacement therapy. Its wearable solution tailors the timing and dose sizes of drugs, preempts predictable peak disease, and addiction symptoms with a device. The company was incorporated in 2003 and is based in Hayward, California.

Vivasure Medical Limited, a medical device company, engages in the research, development, and manufacture of arterial and venous closure devices based on its patented PerQseal technology. The company develops polymer implants and delivery systems that primarily focused on minimally invasive vessel closures in cardiology, interventional radiology, and vascular surgery areas. Its lead product is an absorbable patch-based large-bore percutaneous closure device that is designed to enable closure of large arteriotomies in transcatheter procedures, such as those used for transcatheter aortic valve replacement (TAVR) and endovascular aneurysm repair (EVAR). Vivasure Medical Limited was incorporated in 2008 and is based in Galway, Ireland.

Vivasure Medical Limited, a medical device company, engages in the research, development, and manufacture of arterial and venous closure devices based on its patented PerQseal technology. The company develops polymer implants and delivery systems that primarily focused on minimally invasive vessel closures in cardiology, interventional radiology, and vascular surgery areas. Its lead product is an absorbable patch-based large-bore percutaneous closure device that is designed to enable closure of large arteriotomies in transcatheter procedures, such as those used for transcatheter aortic valve replacement (TAVR) and endovascular aneurysm repair (EVAR). Vivasure Medical Limited was incorporated in 2008 and is based in Galway, Ireland.

MMI S.r.l manufactures and develops micro instruments to support surgical interventions at a dimensional scale. The company develops wristed micro instruments and their fabrication process. The company also develops and offers robotic platform. The company's proprietary robotic platform and wristed micro instruments simplifies reconstruction procedures after traumatic injuries and after tumor removal in breast, head, and bones. The company was founded in 2015 and is headquartered in Calci, Italy.

Cappella, Inc., a Dover, Del.- and Galway, Ireland-based medical device company that is developing novel solutions for the treatment of Complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. The company was founded in 2004 by Antonio Columbo, M.D., Chief of Invasive Cardiology at San Raffaele Hospital in Milan, Italy, and Ascher Shmulewitz, M.D., Ph.D., a cardiologist, medical device entrepreneur and founder of NeoVision, Xcardia and Labcoat Ltd., and established its European headquarters in Galway in 2005.

Neuromod Devices Limited, a medical device company, specializes in the research and development of neuromodulation treatments for chronic tinnitus. Its mutebutton is a bi-modal neuromodulation device that focuses on promoting positive therapeutic change in the human nervous system. The company was founded in 2010 and is based in Dublin, Ireland.

NeRRe Therapeutics Ltd. develops preclinical and clinical neurokinin (NK) receptor antagonists. The company focuses on NK-1 antagonist asset orvepitant as an oral treatment for intense pruritus induced by targeted anti-cancer therapies. It offers NT-814, a NK-1, 3 antagonist; NT-949, a Phase I ready NK-1 antagonist; and NT-432, a NK-1 antagonist clinical candidate. The company was founded in 2012 and is based in Stevenage, United Kingdom.

Cappella, Inc., a Dover, Del.- and Galway, Ireland-based medical device company that is developing novel solutions for the treatment of Complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. The company was founded in 2004 by Antonio Columbo, M.D., Chief of Invasive Cardiology at San Raffaele Hospital in Milan, Italy, and Ascher Shmulewitz, M.D., Ph.D., a cardiologist, medical device entrepreneur and founder of NeoVision, Xcardia and Labcoat Ltd., and established its European headquarters in Galway in 2005.

Neuromod Devices Limited, a medical device company, specializes in the research and development of neuromodulation treatments for chronic tinnitus. Its mutebutton is a bi-modal neuromodulation device that focuses on promoting positive therapeutic change in the human nervous system. The company was founded in 2010 and is based in Dublin, Ireland.

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.

Inflazome is a biotech company that develops orally available drugs to address inflammatory diseases by targeting inflammasomes. The company's drugs block inflammasome signals, eliminating a root cause of inflammation, enabling healthcare institutions to avail targeted therapies for inflammatory diseases such as Parkinson's, Alzheimer's, atherosclerosis, and type 2 diabetes. The company was incorporated in 2016 and is headquartered in Dublin, Ireland.

Vivasure Medical Limited, a medical device company, engages in the research, development, and manufacture of arterial and venous closure devices based on its patented PerQseal technology. The company develops polymer implants and delivery systems that primarily focused on minimally invasive vessel closures in cardiology, interventional radiology, and vascular surgery areas. Its lead product is an absorbable patch-based large-bore percutaneous closure device that is designed to enable closure of large arteriotomies in transcatheter procedures, such as those used for transcatheter aortic valve replacement (TAVR) and endovascular aneurysm repair (EVAR). Vivasure Medical Limited was incorporated in 2008 and is based in Galway, Ireland.

Trino is a drug discovery and early drug development company focused on anti-inflammatory therapeutics. The company is developing drug candidates from a novel, proprietary, class of drugs based on indane dimers derived from a Taiwanese fern. Its lead candidate is a potential first-in-class drug for the treatment of inflammatory bowel disease (IBD), which could be used in both ulcerative colitis (UC) and Crohn’s disease (CD). Trino’s drug class also offers promising candidates with a broad anti-inflammatory activity that could be suitable for applications in dermatology, pulmonary and auto-immune disease.

Civitas Therapeutics is a biopharmaceutical company that focuses on developing pulmonary delivery therapies. The Company develops therapeutics for the treatment of central nervous system and respiratory disorders. It serves patients throughout the United States.

Neuravi Limited designs and develops clot retrieval devices for restoring blood flow in patients who have suffered ischemic strokes due to blockage of an artery to the brain. It offers EmboTrap revascularization devices for the treatment of acute ischemic strokes to patients in Belgium, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Norway, Spain, Sweden, and Switzerland. The company was incorporated in 2009 and is based in Galway, Ireland. As of April 10, 2017, Neuravi Limited operates as a subsidiary of DePuy Ireland Unlimited Company.

Neurent Medical Limited develops medical device for treating rhinitis. The company offers a single-use device for ENT surgeons to treat both allergic and non-allergic rhinitis. The company was founded in 2015 and is headquartered in Galway, Ireland.

Drug development firm focused on immunology. They are headquartered in Dublin, Ireland. Opsona Therapeutics is one of Europe's most innovative and dynamic drug development companies. We are at the forefront of drug development in immunology research, with particular focus on the innate immunity pathways. Since its founding in 2004, Opsona has validated and developed a series of exciting new drug candidates and strategies which modulate the human innate immune system. We are located in Dublin, Ireland.

Neuromod Devices Limited, a medical device company, specializes in the research and development of neuromodulation treatments for chronic tinnitus. Its mutebutton is a bi-modal neuromodulation device that focuses on promoting positive therapeutic change in the human nervous system. The company was founded in 2010 and is based in Dublin, Ireland.

Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations, focused on the development of transformative therapies for the treatment of worsening and acute decompensated heart failure.

Neuromod Devices Limited, a medical device company, specializes in the research and development of neuromodulation treatments for chronic tinnitus. Its mutebutton is a bi-modal neuromodulation device that focuses on promoting positive therapeutic change in the human nervous system. The company was founded in 2010 and is based in Dublin, Ireland.